Biota Pharmaceuticals Announces Appointment of Mark P. Colonnese as Chief Financial Officer
November 02 2015 - 7:00AM
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical
company focused on the discovery and development of direct-acting
antivirals that address infections that have limited therapeutic
options, announced today the appointment of Mark P. Colonnese as
Executive Vice President and Chief Financial Officer, effective
immediately.
"Mark has broad and extensive industry expertise and has been
implementing strategic financial strategies for over 30 years. We
are pleased to have him join our executive team as we continue to
develop our novel direct-acting antiviral pipeline and as we look
forward to the upcoming year, in which we anticipate Phase 2 data
readouts from our three programs, vapendavir, BTA074 and BTA585,"
commented Joseph M. Patti, PhD, President and Chief Executive
Officer of Biota.
Prior to joining Biota, Mark was Chief Financial Officer (CFO)
of Stealth BioTherapeutics, Inc. Previously, Mark served as
Executive Vice President (EVP) and CFO at Transgenomic. He has also
served as EVP, commercial operations and CFO at AtheroGenics, where
he raised $450 million in debt and equity capital, led the company
through its initial public offering process and helped negotiate a
worldwide partnership agreement with AstraZeneca. Mark has also
held a number of executive and management positions at
Schering-Plough Corporation. He holds an MBA from Fairleigh
Dickinson University, a BS, magna cum laude, from Ithaca College,
and is a Certified Public Accountant.
Mr. Colonnese commented, "As a global leader in the development
of direct-acting antiviral therapies, and with its robust portfolio
of novel compounds, Biota is an exciting growth story and I look
forward to working with the team to develop strategies that will
further accelerate shareholder value creation."
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and
development of direct-acting antivirals to treat infections that
have limited therapeutic options and affect a significant number of
patients globally. The Company has four product candidates in
clinical development. These include vapendavir, an oral treatment
for human rhinovirus infections in moderate-to-severe asthmatics
that is currently being evaluated in the Company's ongoing Phase 2b
SPIRITUS trial; BTA074, a topical antiviral treatment in Phase 2
development for genital warts caused by human papillomavirus types
6 & 11; BTA585, an oral fusion (F) protein inhibitor in Phase 1
development for the treatment of respiratory syncytial virus (RSV)
A & B infections; and laninamivir octanoate, a one-time,
inhaled treatment in Phase 2 development for influenza A and B
infections. The Company also has a preclinical stage RSV non-fusion
inhibitor program that it believes can complement its
fusion-protein inhibitor BTA585. For additional information about
the Company, please visit www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve known and unknown risks and uncertainties concerning
Biota Pharmaceuticals, Inc. business, operations and financial
performance. Any statements that are not of historical facts may be
deemed to be forward-looking statements, including the time frame
in which the Company anticipates reporting top-line data from Phase
2 trials of vapendavir, BTA074 and BTA585. Other cautionary
statements contained elsewhere in this press release and in the
Company's Annual Report on Form 10-K for the year ended June 30,
2015, as filed with the U.S. Securities and Exchange Commission on
September 11, 2015. There may be events in the future that the
Company is unable to predict, or over which it has no control, and
the Company's business, financial condition, results of operations
and prospects may change in the future. The Company may not update
these forward-looking statements more frequently than quarterly
unless it has an obligation under U.S. Federal securities laws to
do so.
CONTACT: Joseph M. Patti, PhD
President and Chief Executive Officer
(678) 221-3352
j.patti@biotapharma.com
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024